Jiangsu Alpha Pharmaceutical Co., Ltd.

News

New Green Synthesis Route for Atorvastatin Calcium and Intermediates Achieves Stable High Purity

A newly developed green synthesis route for Atorvastatin Calcium and intermediates has passed continuous pilot operation assessment and been officially put into production at Jiangsu Alpha Pharmaceutical Co., Ltd. Different from conventional chemical synthesis pathways that rely heavily on chemical reduction and harsh reaction conditions, this new route adopts a chemo-enzymatic cascade strategy. Engineered ketoreductase is applied to carry out stereoselective reduction under mild aqueous conditions, which greatly reduces the dependence on hazardous chemical reagents and high-pressure reaction equipment.

The new synthetic design shortens the overall reaction sequence and simplifies complicated post-treatment purification steps. Strict closed-loop control is implemented on reaction temperature, pH value, substrate feeding ratio and enzyme dosage. Such precise parameter management ensures consistent high purity and excellent enantiomeric excess across different batches. The finished intermediates are tested against impurity limits and analytical specifications referenced from major international pharmacopoeia. The internal quality team continuously carries out stability monitoring and analytical method validation, preparing complete technical documentation packages for global regulatory submission.

This scalable green route represents a low-carbon technical option for global research teams engaged in atorvastatin calcium and other statin drug projects. By lowering waste generation and reducing purification pressure, the process helps cut the overall environmental footprint of statin raw material manufacturing. Jiangsu Alpha Pharmaceutical will continue to expand the application of biocatalysis platforms, and extend similar green process concepts to other cardiovascular pharmaceutical intermediates in its product portfolio.